We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Reduced Threat-Related Neural Efficiency as a Biomarker for Pediatric Anxiety: Implications for Diagnosis and CBT Response

MedXY Editorial Team•Oct 30, 2025•news
biomarkersCognitive Behavioral Therapy

Highlight

1. Neural efficiency, measured as similarity in brain network connectivity between rest and threat-related tasks, shows reduced values in youths with anxiety disorders compared to healthy controls.

2. Reduced neural efficiency correlates with both anxiety diagnosis and symptom severity, indicating its potential as a dimensional biomarker.

3. Baseline neural efficiency predicts response to exposure-based cognitive-behavioral therapy (CBT), with lower efficiency associated with poorer treatment outcomes.

4. Neural efficiency demonstrates moderate test-retest reliability over 11 to 18 weeks in healthy youths, supporting its stability as a biomarker candidate.

Study Background

Pediatric anxiety disorders are among the most prevalent psychiatric conditions in youths and are strong predictors of adult psychopathology. Despite their high prevalence and significant impact on functioning, current treatments, including cognitive-behavioral therapy (CBT), achieve sustained remission in fewer than half of affected youths. This highlights a critical unmet need for mechanistically informed biomarkers that can improve diagnosis, predict treatment response, and guide personalized interventions to enhance therapeutic efficacy in this population.

Study Design

This research enrolled 103 youths diagnosed with anxiety disorders (mean age 12.5 years, SD=2.91; 62% female) and compared them to 103 age-matched healthy controls without psychiatric diagnosis (mean age 13.4 years, SD=2.58; 53% female). Participants underwent functional magnetic resonance imaging (fMRI) scans during two conditions: resting state and an active dot-probe task involving threatening faces, a well-established paradigm probing threat processing.

Neural efficiency was operationalized as the partial correlation between intrinsic (resting state) and task-evoked functional connectivity patterns across the whole brain. This metric captures the degree to which brain network configurations during threat processing resemble baseline resting connectivity, with higher similarity indicating more efficient neural reconfiguration.

The study included test-retest reliability assessments at 4 months (11–18 weeks) in healthy youth to evaluate biomarker stability. Additionally, the anxious participants—80 of whom subsequently received exposure-based CBT—were examined longitudinally to determine whether neural efficiency at baseline predicted treatment response.

Key Findings

1. Test-Retest Reliability: Neural efficiency showed acceptable stability over 4 months in healthy youths, with an intraclass correlation coefficient (ICC) of 0.65, indicating moderate reliability for clinical biomarker considerations.

2. Neural Efficiency and Anxiety Diagnosis: Comparisons revealed significantly reduced neural efficiency in youths with anxiety disorders relative to controls (t=2.62; Cohen’s d=0.29), supporting its role as a state or trait marker of pediatric anxiety.

3. Dimensional Symptom Associations: Neural efficiency negatively correlated with anxiety symptom severity (r=-0.18), underscoring its relevance across diagnostic boundaries and potential use as a dimensional biomarker reflecting underlying neural dysfunction.

4. Prediction of CBT Response: Importantly, baseline neural efficiency did not change after CBT but significantly predicted treatment response magnitude. Lower initial neural efficiency was associated with poorer outcomes (β = -11.88, χ² = 9.20) in the subset of 80 youths undergoing therapy, indicating prognostic utility for guiding personalized treatment planning.

Expert Commentary

The concept of ‘neural efficiency’—how flexibly the brain can reconfigure its functional networks in response to threat stimuli—offers a promising neurobiological target for understanding anxiety. Reduced neural efficiency may reflect impaired neural adaptability or excessive intrusion of threat-related processes, consistent with cognitive theories of anxiety that posit aberrant threat monitoring and processing as central features.

These findings align with emerging research identifying network-level biomarkers in psychiatric disorders that transcend traditional symptom-based categories, potentially enabling more objective and mechanistically informed diagnostic frameworks.

While the test-retest reliability and predictive validity presented are encouraging, the effect sizes are modest, and further replication in larger, diverse cohorts is essential before clinical implementation. Additionally, longitudinal studies investigating whether interventions can enhance neural efficiency and subsequently improve therapeutic outcomes could deepen mechanistic insights and treatment innovation.

It is also important to consider individual variability in developmental trajectories and comorbidities that might influence neural efficiency metrics. Multi-modal neuroimaging and integration with genetic, behavioral, and environmental data would enrich biomarker characterization.

Conclusion

This study identifies reduced threat-related neural efficiency, defined as diminished similarity in functional brain network connectivity between resting state and processing of threatening stimuli, as a potential biomarker for pediatric anxiety disorders. Neural efficiency shows promise in both diagnostic classification and as a predictor of response to CBT, addressing significant gaps in pediatric anxiety care.

Incorporating neural efficiency assessments into clinical protocols could facilitate stratification of anxious youths, guiding targeted intervention strategies and informing the design of novel therapeutics aimed at enhancing brain network adaptability. Future work should focus on validating these findings across heterogeneous populations, exploring neural efficiency as an intervention target, and integrating biomarker data into precision psychiatry frameworks.

Funding and ClinicalTrials.gov

The original study was published in the American Journal of Psychiatry and supported by relevant institutional and research funding. The clinical trial registry information was not specified in the excerpt.

References

Linke JO, Naim R, Haller SP, Khosravi P, Scheinberg B, Byrne ME, Harrewijn A, Leibenluft E, Brotman MA, Winkler AM, Pine DS. Reduced Threat-Related Neural Efficiency: A Possible Biomarker for Pediatric Anxiety Disorders. Am J Psychiatry. 2025 Oct 8:appiajp20241043. doi: 10.1176/appi.ajp.20241043. Epub ahead of print. PMID: 41058235.

Additional relevant literature on neural efficiency and pediatric anxiety neuroimaging includes:

  • Drysdale AT, Grosenick L, Downar J et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2017 Jan;23(1):28-38.
  • Price RB, Rasenick MM, Bailey RK. Modulating cortical oscillations with transcranial alternating current stimulation in psychiatric disorders. Front Psychiatry. 2020;11:513.
  • Kumar P, Clark M. Clinical Medicine. 11th ed. Elsevier; 2019. Chapter on anxiety disorders.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Unlocking the Potential of Novel Biomarkers for Acute Kidney Injury in the Critically Ill: A Comprehensive Evidence MappingThis article reviews over 1100 studies on novel biomarkers for acute kidney injury (AKI) in critically ill patients, highlighting their predictive, diagnostic, and management roles while identifying gaps for future clinical implementation.Sep 18, 2026Blood Transcriptomic Signatures as Predictors of Poor Outcomes in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Brazilian CohortHost blood transcriptomic signatures effectively monitor treatment response and predict recurrence and mortality in drug-susceptible pulmonary tuberculosis, meeting WHO benchmarks and enabling personalized therapy strategies.Sep 17, 2026Advancing Fetal Death Detection: Identification of Novel Maternal Plasma Biomarkers Through Large-Scale Proteomic ProfilingLarge-scale proteomic analysis identifies novel maternal plasma protein biomarkers that improve detection of fetal death beyond established markers, highlighting both shared and unique pathological pathways with preeclampsia.Sep 12, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Decoding Neuroendocrine Carcinomas: Proteomic Insights Define Subtypes, Biomarkers, and Therapeutic Opportunities
Comprehensive proteomic and phosphoproteomic profiling of 267 neuroendocrine carcinomas across multiple tissues reveals distinct molecular subtypes, biomarkers, and a novel NAD+ metabolic vulnerability, advancing personalized precision medi
Aug 28, 2026
Plasma POMC as a Predictive Biomarker for Silent Corticotroph Adenomas in Non-Functioning Pituitary TumorsElevated plasma pro-opiomelanocortin (POMC) levels accurately predict silent corticotroph adenomas (SCAs) among clinically non-functioning pituitary adenomas, offering a promising tool for diagnosis and monitoring.Aug 27, 2026
Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-ScoresSerum neurofilament light chain (sNfL) z-score dynamics enhance monitoring of treatment response in relapsing multiple sclerosis (RMS), providing complementary predictive value for disease activity beyond conventional clinical and MRI assesAug 21, 2026